Bliss GVS Pharma received an addendum to its open offer announcement, adding Mates Visa Consultancy Private Limited to the acquirer group. This is a procedural update with no change to the offer size or terms.
Bliss GVS Pharma Open Offer Addendum Received
Bliss GVS Pharma Limited announced an addendum to its ongoing open offer, dated July 17, 2026. The addendum was issued by SBI Capital Markets Limited, the Manager to the Open Offer. ## What just happened The primary change detailed in the addendum is the inclusion of Mates Visa Consultancy Private Limited as a 'person acting in concert' (PAC) with Anupam Rasayan India Limited, the main acquirer. This update pertains to the open offer for up to 27,726,848 equity shares of Bliss GVS Pharma, representing 26.00% of the expanded voting share capital. ## Why this matters This update clarifies the complete group of entities participating in the acquisition of Bliss GVS Pharma. For existing shareholders, it provides a more precise picture of who is involved in the potential takeover. The SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, govern this process, ensuring compliance and transparency. ## The backstory Bliss GVS Pharma is involved in the pharmaceutical sector. Anupam Rasayan India Limited is an established chemical manufacturer. The initial open offer was announced earlier, and this addendum is a procedural refinement. ## What changes now This addendum does not alter the size or the fundamental terms of the open offer itself, such as the offer price or the percentage of shares being acquired. It simply formalizes the role of Mates Visa Consultancy Private Limited within the acquirer's consortium. ## Risks to watch While this is a procedural update, any changes to the acquirer group could potentially indicate shifts in strategic intent, though none are explicitly stated here. Shareholders should continue to monitor the progress and any further announcements related to the open offer. ## Peer comparison Open offers are common mechanisms for consolidation and strategic stake acquisition in the Indian market. Bliss GVS Pharma operates in the pharmaceutical sector, while Anupam Rasayan is in the chemical industry, suggesting a potential backward or forward integration play or simply a financial investment. ## Context metrics (time-bound) The addendum is dated July 17, 2026. The open offer aims to acquire up to 27,726,848 equity shares, which is 26.00% of the expanded share capital. ## What to track next Investors should track the response to the open offer and any further communication from Bliss GVS Pharma or the acquirer group regarding the tendering of shares and the final outcome of the offer.
